USING QCT TO DETECT DRUG-INDUCED OSTEOPOROSIS IN PATIENTS WITH MENTAL DISORDERS

In clinical practice, the assessment of the cumulative risk of drug-induced osteoporosis in patients with mental disorders is difficult because there are no algorithms to reveal patients with a high risk of antipsychotic-induced osteoporosis and BMD is not evaluated in patients with mental disorders. 95 patients aged from 21 to 60 years with a mental illness duration of at least 12 months on antipsychotics and anticonvulsants therapy were examined. 23 patients (24%) had shown a violation of BMD. There is a significant correlation between the number of risk factors and a decrease in BMD. However, additional study of pharmacogenetic and laboratory data on the risk of osteoporosis is required, which will make it possible to plan therapy more precisely, additionally prescribe drugs that regulate BMD in these categories of patients.

1. Stewart T., Ralston S. Role of genetic factors in the pathogenesis of osteoporosis // Journal of Endocrinology. Bioscientifica. 2000. Vol. 166 (2). P. 235–245. http://dx.doi.org/10.1677/joe.0.1660235.

2. Ratti C., Vulcano E., Canton G., Marano M., Murena L., Cherubino P. Factors affecting bone strength other than osteoporosis // Aging. Clinical and Experimental. Research. Springer. Nature. 2013. Vol. 25 (1). P. 9–11. http://dx.doi.org/10.1007/s40520-013-0098-6.

3. Johnell O., Kanis J.A. Anestimate of the world wide prevalence and disability associated with osteoporotic fractures // Osteoporos Int. 2006. Vol. 17. P. 1726–1733. http://dx.doi.org/10.1007/ s00198-006-0172-4.

4. Мельниченко Г.А., Мамедова Е.О. Ятрогенные поражения скелета // Ожирение и метаболизм. 2016. Т. 12, № 2. С. 41–47. [Melnichenko G.A., Mamedova E.O. Yatrogennye porazheniya skeleta. Ozhirenie i metabolizm, 2016, Vol. 12, No. 2, рр. 41–47. (In Russ.)].

5. Горобец Л.Н., Поляковская Т.П., Литвинов А.В., Василенко Л.М., Буланов В.С. Проблема остеопороза у больных с психическими расстройствами при нейролептической терапии. Часть 1 // Социальная и клиническая психиатрия. 2012. Т. 22, № 3. С. 107–112. [Gorobec L.N., Polyakovskaya T.P., Litvinov A.V., Vasilenko L.M., Bulanov V.S. Problema osteoporoza ubolnyh s psihicheskimi rasstrojstvami pri nejrolepticheskoj terapii. Chast 1. Socialnaya i klinicheskaya psihiatriya. 2012, Vol. 22, No. 3, рр. 107–112. (In Russ.)].

6. Горобец Л.Н., Поляковская Т.П., Литвинов А.В., Василенко Л.М., Буланов В.С. Проблема остеопороза у больных с психическими расстройствами при нейролептической терапии. Часть 2 // Социальная и клиническая психиатрия. 2012. T. 23, № 1. С. 87–92. [Gorobec L.N., Polyakovskaya T.P., Litvinov A.V., Vasilenko L.M., Bulanov V.S. Problemaosteoporoaz u bolnyh s psihicheskimi rasstrojstvami pri nejrolepticheskoj terapii. Chast 2. Socialnaya i klinicheskaya psihiatriya, 2012, Vol. 23 No. 1, рр. 87–92. (In Russ.)].

7. Мазо Г.Э., Горобец Л.Н. Осложнения нейролептической гиперпролактинемии // Обозрение психиатрии и медицинской психологии им. В. М. Бехтерева. 2018. № 2. С. 104–108. [Mazo G.E., Gorobec L.N. Oslozhneniya nejrolepticheskoj giperprolaktinemii. Obozrenie psihiatrii i medicinskoj psihologii imeni V. M. Behtereva, 2018, No. 2, рр. 104–108. (In Russ.)].

8. Salimipour H. et al. Antiepileptic treatmentis associated with bone loss: difference indrug type and region of interest // Journal of nuclear medicine technology. 2013. Vol. 41, No. 3. Р. 208–211. http://dx.doi.org/10.2967/jnmt.113.124685.

9. Kahl K.G., Greggersen W., Rudolf S. Bonemineraldensity, boneturnover, and osteoprotegerinin depressed women with and without border line personality disorder // Psychosom. Med. 2006. Vol. 68. Р. 669–674. http://dx.doi.org/10.1097/01.psy.0000237858.76880.3d.

10. Hofbauer L.C., Hamann Ch., Ebeling P.R. Approach to the patient with secondary osteoporosis // Eur. J. Endocrinol. 2010. Vol. 162. Р. 1009–1020. http://dx.doi.org/10.1530/eje-10-0015.

11. Huybrechts K.F., Rothman K.J., Silliman R.A. et al. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes // Can. Med. Assoc. J. 2011. Vol. 183. Р. 411–419. http://dx.doi.org/10.1503/cmaj.101406.

12. Partti K., Heliovaara M. Skeletal status in psychotic disorders: a population- based study // Psychosom. Med. 2010. Vol. 72 (9). P. 933–940/19. http://dx.doi.org/10.1097/psy.0b013e3181f7abd3.

13. Gage S.H., Jones H.J., Taylor A.E., Burgess S., Zammit S., Munafò M.R. Investigatingcausalityinassociationsbetweensmokinginitiationandschizophreniausing Mendelianr an domization. Scientific. Reports // Springer Nature. 2017. Vol. 7 (1). http://dx.doi.org/10.1038/srep40653.

14. Piotrowski P., Gondek T.M, Krolicka-Deregowska A., Misiak B., Adamowski T., Kiejna A. Causes of mortality in schizophrenia: anup datedre view of Europe an studies // Psychiatr. Danub. 2017. Vol. 29. P. 108–120. http://dx.doi.org/10.24869/psyd.2017.108.

15. Driver J., Weber C.E., Callaci J.J., Kothari A.N., Zapf M.A., Roper P.M., Borys D., Franzen C.A., Gupta G.N., Wai P.Y., Zhang J., Denning M.F., Kuo P.C., Mi Z., Alcohol Inhibits Osteopontin-dependent Transforming Growth Factor- 1 Expression in Human Mesenchymal Stem Cells // Journal of Biological Chemistry. 2015. Vol. 290 (16). Р. 9959–9973. https://doi.org/10.1074/jbc.M114.616888.

16. Zai C.C., Manchia M., Zai G.C., Woo J., Tiwari A.K., de Luca V., Kennedy J.L. Associationstudy of BDNF and DRD3 genes with alcohol use disorder in Schizophrenia // Neuroscience Letters. 2018. Vol. 671. P. 1–6. http://dx.doi.org/10.1016/j.neulet.2018.01.033.

17. Adams J.E. Quantitative computed tomography // Eur. J. Radiol. 2009. Vol. 71 (3). P. 415–424. http://dx.doi.org/10.1016/j.ejrad.2009.04.074.

18. Bushe C., Bradley A., Pendlebury J. A review of hyperprolactinaemia and severe mental illness: Are the reimplications for clinical biochemistry? // Ann. Clin. Biochem. 2010. Vol. 47. Р. 292–300. http://dx.doi.org/10.1258/acb.2010.010025.

19. Holt R.I., Peveler R.C. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management // Clin. Endocrinol. 2011. Vol. 74, 2. Р. 141–147. http://dx.doi.org/10.1111/j.1365–2265.2010.03814.x.

20. Shen C., Chen F., Zhang Y. Association betweenuse of antiepileptic drugs and fracture risk: A systematic review and meta-analysis // Bone. 2014. Vol. 64. P. 246–253. http://dx.doi.org/10.1016/j.bone.2014.04.018.

21. Elliott J.O., Moore J.L., Lu B. Health status and behavioral risk factors among persons with epilepsy in Ohiobased on the 2006 Behavioral Risk Factor Surveillance System // Epilepsy Behav. 2008. Vol. 12 (3). P. 434–444. http://dx.doi.org/10.1016/j.yebeh.2007.12.001.

22. Meier C., Kraenzlin M.E. Antiepileptics and bone health // Therapeutic Advancesin Musculoskeletal Disease. SAGE Publications. 2011. Vol. 3 (5). P. 235–243. http://dx.doi.org/ 10.1177/1759720x11410769.

23. El-HajjFuleihan G., Dib L., Yamout B., Sawaya R., Mikati M.A. Predictors of bone density in ambulatory patients on antiepileptic drugs // Bone. 2008. Vol. 43. P. 149–155. http://dx.doi.org/10.1016/j.bone.2008.03.002.

24. Verrotti A., Coppola G., Parisi P., Mohn A., Chiarelli F. Bone and calcium metabolism and antiepileptic drugs // Clin. Neurol. Neurosurg. 2010. Vol. 112. P. 1–10. http://dx.doi.org/10.1016/j.clineuro.2009.10.011.

25. Lee R., Lyles K., Sloane R., Colón-Emeric C. The association of newer anticonvulsant medications and bone mineral density // Endocr. Pract. 2012. Vol. 14. P. 1–22. http://dx.doi.org/10.4158/ep12119.or.

26. Tarride J.E., Hopkins R.B., Leslie W.D. et al. The burden of illness of osteoporosis in Canada // Osteoporos. Int. 2012. Vol. 23. P. 2591–2600. http://dx.doi.org/10.1007/s00198-012-1931-z

27. Морозов С.П. Диагностика остеопороза с помощью асинхронной КТ- денситометрии // Opinion. Leader. 2018. № 1 (9). С. 28–30. [Morozov S.P Diagnostika osteoporoza s pomoshy uasinhronnoj KTdensitometrii. Opinion Leader, 2018, No. 1 (9), рр. 28–30 (In Russ.)].

28. Насырова Р.Ф., Шнайдер Н.А., Миронов К.О., Шипулин Г.А., Дрибноходова О.П., Голосов Е.А., Толмачев М.Ю., Андреев Б.В., Курылев А.А., Ахметова Л.Ш., Лиманкин О.В., Незнанов Н.Г. Фармакогенетика шизофрении в реальной клинической практике // Неврология, нейропсихиатрия, психосоматика. 2018. Т. 10, № 4. С. 88–93. [Nasyrova R.F., Schnaider N.A., Mironov K.O., Shipulin G.A., Dribnokhodova O.P., Golosov E.A., Tolmachev M.Y., Andreev B.V., Kurylev A.A., Akhmetova L.S., Limankin О.V., Neznanov N.G. Pharmacogenetics of schizophrenia in real clinical practice: a clinical case. Neurology, Neuropsychiatry, Psychosomatics, 2018, No. 10 (4), pp. 88–93. (In Russ.)] https://doi.org/10.14412/2074-2711-2018-4-88-93.